Rigel Announces Participation in Upcoming Investor and Partnering Conferences

Date : 03/13/2008 @ 7:30AM
Source : PR Newswire
Stock : Rigel Pharmaceuticals (MM) (RIGL)
Quote : 16.41  -2.53 (-13.36%) @ 8:00PM
<< BackQuote Chart Financials

 



Rigel Announces Participation in Upcoming Investor and Partnering Conferences

SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 11th Annual Lehman Brothers Global Healthcare Conference in Miami, Florida on Tuesday, March 18 at 4:45 p.m. EDT.

Mr. Gower is also scheduled to participate in a panel discussion titled "Biotech Models: Should you Just Go to POC or Should you Go All the Way? A Look at Both-Pros/Cons", at the 2008 Pharmaceutical Strategic Outlook Conference hosted by Windhover Information in New York City on March 20 at 10:30 a.m. EDT.

To access the live audio webcast of the investor presentation or the subsequent archived recording, log on to http://www.rigel.com/. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (http://www.rigel.com/)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Contact: Ryan Maynard Phone: 650.624.1284 Email:

http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGO

http://photoarchive.ap.org/

DATASOURCE: Rigel Pharmaceuticals, Inc.

CONTACT: Ryan Maynard of Rigel Pharmaceuticals, Inc., +1-650-624-1284,

Web site: http://www.rigel.com/

<< Back


Rigel Pharmaceuticals (MM) Historical Chart Rigel Pharmaceuticals (MM) Intraday Chart  
Period
noad


LSE and PLUS quotes are live. NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions :: Contact Us :: Request an Exchange :: Affiliate Scheme
Copyright1999-2008 ADVFN PLC. Copyright and limited reproduction :: Privacy Policy :: Investment Warning :: Advertise with us :: Data accreditations :: Investor Relations :: Press office :: Jobs
ADDITIONAL SERVICES AVAILABLE FROM ADVFN
Upgrade - Click here for more information on ADVFN premium services Money Words - ADVFN Financial Glossary Investor Training ADVFN Financial Bookshop Online Training Academy
42 site:2us 081015 21:04 Stock Message Boards ( 2001 | 2002 | 2003 | 2004 | 2005 | 2005 | 2007 )